Tuesday, June 04, 2024 8:00:02 AM
Looking forward to 10-K, 10-Q. Not expecting much other than hopefully seeing further evidence of institutional and insiders lining up behind equity positions here and further eliminating debts and warrants overhanging. I think they can be positioned to eliminate all potential conversions and not need to utilize the entire 2B authorized. Big difference in stock price if they can keep share structure closer to 1 bil versus needing 2 bil or more to execute on their pipeline. Plus filings up to date will confirm to many a solid foundation going forward, so would be a catalyst to some investors.
I think we see this continually strengthen, with consolidation days mixed in until we hear more about pipeline progress. The OSA program has some investment lined up, and presumably doing preclinical work on new formulations. Any details regarding progress with OSA would be a catalyst. IMO, the bigger catalysts is their dealings with NIH and having KRM-ll-81 make it to final stages (tier 3) of their robust preclincal process. Researching all the extensive preclinical efforts with this candidate drug AND the success thus far for BOTH epilepsy and pain indications, I can forsee multiple BP deals come from this effort. These would be absolutely huge and dwarf past storied stocks. Obvious risk in any drug development, but as longs here can attest, the potential is flat out amazing. Reading all the filings too, you can see insiders, etc positioning for success. Nothing is guaranteed, but risk v reward is why speculative money is here on the OTC. GLTA.
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 12:45:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 12:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
FEATURED SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • Oct 3, 2024 7:00 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM